INCX (6861) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 睿生光電

INCX (6861) reported revenue of NT$240.3 million for Oct 2026, +4.1% year on year and -19.9% from the previous month. Revenue for Jan–Oct 2026 was NT$2.66 billion (+42.1% year on year).

Year-on-year revenue growth: 17 months in a row. →

In Oct 2026, it ranked No. 38 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$161.3 million24/10Nov 2024 NT$172 millionDec 2024 NT$204.5 millionJan 2025 NT$176.4 millionFeb 2025 NT$180.6 million25/02Mar 2025 NT$179.8 millionApr 2025 NT$187.6 millionMay 2025 NT$159.7 millionJun 2025 NT$203.5 million25/06Jul 2025 NT$178 millionAug 2025 NT$185.9 millionSep 2025 NT$190.9 millionOct 2025 NT$230.8 million25/10Nov 2025 NT$203.6 millionDec 2025 NT$217 millionJan 2026 NT$256.7 millionFeb 2026 NT$260.1 million26/02Mar 2026 NT$274.3 millionApr 2026 NT$262.2 millionMay 2026 NT$265.7 millionJun 2026 NT$229.1 million26/06Jul 2026 NT$290.8 millionAug 2026 NT$283.5 millionSep 2026 NT$299.9 millionOct 2026 NT$240.3 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$240.3 million+4.1%-19.9%
Sep 2026NT$299.9 million+57.1%+5.8%
Aug 2026NT$283.5 million+52.5%-2.5%
Jul 2026NT$290.8 million+63.4%+26.9%
Jun 2026NT$229.1 million+12.6%-13.8%
May 2026NT$265.7 million+66.4%+1.4%
Apr 2026NT$262.2 million+39.7%-4.4%
Mar 2026NT$274.3 million+52.6%+5.5%
Feb 2026NT$260.1 million+44.0%+1.3%
Jan 2026NT$256.7 million+45.5%+18.3%
Dec 2025NT$217 million+6.1%+6.5%
Nov 2025NT$203.6 million+18.4%-11.8%
Oct 2025NT$230.8 million+43.1%+20.9%
Sep 2025NT$190.9 million+14.5%+2.7%
Aug 2025NT$185.9 million+24.0%+4.5%
Jul 2025NT$178 million+6.6%-12.5%
Jun 2025NT$203.5 million+23.1%+27.4%
May 2025NT$159.7 million-7.8%-14.9%
Apr 2025NT$187.6 million+9.4%+4.4%
Mar 2025NT$179.8 million+18.6%-0.5%
Feb 2025NT$180.6 million+27.6%+2.4%
Jan 2025NT$176.4 million+6.8%-13.7%
Dec 2024NT$204.5 million+18.4%+18.9%
Nov 2024NT$172 million+5.5%+6.6%
Oct 2024NT$161.3 million-4.7%-3.3%

Jan–Oct 2026 cumulative: NT$2.66 billion (+42.1% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: INCX vs PEC / INCX vs Lotus Pharm / INCX vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16